Literature DB >> 2345710

Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).

K K Flaharty1.   

Abstract

Recombinant human erythropoietin reverses the severe anemia associated with end-stage renal disease. Mean half-life values after a single intravenous bolus dose range from 4-13 hours. Renal clearance is not a significant route of elimination. Dosing schedules in chronic renal failure involve a single intravenous bolus dose administered three times weekly after hemodialysis. Subcutaneous dosing has been approved and may be used in patients without intravenous access. Reticulocyte counts and hematocrit levels exhibit dose-dependent increases; improved hematocrit levels can be sustained with maintenance doses.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2345710

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  8 in total

1.  Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.

Authors:  Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

2.  Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.

Authors:  Dana L Long; Daniel H Doherty; Stephen P Eisenberg; Darin J Smith; Mary S Rosendahl; Kurt R Christensen; Dean P Edwards; Elizabeth A Chlipala; George N Cox
Journal:  Exp Hematol       Date:  2006-06       Impact factor: 3.084

Review 3.  Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Authors:  R Whittington; L B Barradell; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

4.  Human erythropoietin dimers with markedly enhanced in vivo activity.

Authors:  A J Sytkowski; E D Lunn; K L Davis; L Feldman; S Siekman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

5.  Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.

Authors:  Alan J Bitonti; Jennifer A Dumont; Susan C Low; Robert T Peters; Keith E Kropp; Vito J Palombella; James M Stattel; Yichun Lu; Cristina A Tan; Jeffrey J Song; Ana Maria Garcia; Neil E Simister; Gerburg M Spiekermann; Wayne I Lencer; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

6.  Production of Erythropoietin-Specific Polyclonal Antibodies.

Authors:  Kourosh Maboudi; Seyedeh Marzieh Hosseini; Mina Sepahi; Hashem Yaghoubi; Shahin Hadadian
Journal:  Iran J Biotechnol       Date:  2017-03       Impact factor: 1.671

7.  Erythropoiesis stimulating agents: approaches to modulate activity.

Authors:  Angus M Sinclair
Journal:  Biologics       Date:  2013-07-03

8.  Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers.

Authors:  Sumin Yoon; Su-Jin Rhee; Sun Ju Heo; Tae Young Oh; Seo Hyun Yoon; Joo-Youn Cho; SeungHwan Lee; Kyung-Sang Yu
Journal:  Drug Des Devel Ther       Date:  2017-10-27       Impact factor: 4.162
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.